INTRODUCING A RANGE OF THERAPEUTIC STRENGTHS THAT

ALLOWS YOU TO DO MORE FOR YOUR AD PATIENTS

 

 Higher-dose benefits with EXELON PATCH 15 cm2 (13.3 mg/24 hrs) are here

 

* The Investigation of transDermal EXELON in ALzheimer’s disease (IDEAL) trial was a 6-month, double-blind, randomized, placebo-controlled study.

The purpose of IDEAL was to assess the comparative safety and efficacy of EXELON PATCH 10 cm2 vs 12 mg/day rivastigmine capsules in patients with AD.2

** The OPtimizing Transdermal EXELON In Mild-to-moderate Alzheimer’s disease (OPTIMA) was a 72- to 96-week multicenter trial, comprised of a 24- to 48-week

independent open-label phase, followed by a 48-week randomized, double-blind, parallel-group phase. The purpose of OPTIMA was to assess the comparative

efficacy, safety, and tolerabilityof EXELON PATCH 10 cm2 and 15 cm2 in patients with AD showing functional and cognitive decline.3

 

 

Video: Differential early diagnosis - Dr Small 

 

×

Medical Information Request

×

Ask Speakers